Shares of Vertex Pharmaceuticals Inc. plunged 10.03% to $450.03 Tuesday, on what proved to be an all-around grim trading ...

Vertex Pharmaceuticals is pressing pause on a phase 1/2 cystic fibrosis (CF) trial over a tolerability issue while reporting ...

Relay Therapeutics, Inc. engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its Dynamo platform is use ...

Bottom-up research on individual companies drives stock selection. As a result, the portfolio’s sector and country positioning often contrast with the strategy’s MSCI ACWI ex USA Value Index ...

Arcutis Biotherapeutics, Inc. (ARQT) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.32 per share a year ago.

Real time quote data is not available at this time. *Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green ...

Real time quote data is not available at this time. *Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green ...